Document is current
Any future updates will be listed below
-
Authors
Hollestein, Viola https://orcid.org/0000-0002-6326-4172
Poelmans, Geert https://orcid.org/0000-0001-7039-6985
Forde, Natalie J.
Beckmann, Christian F.
Ecker, Christine
Mann, Caroline
Schäfer, Tim
Moessnang, Carolin
Baumeister, Sarah
Banaschewski, Tobias https://orcid.org/0000-0003-4595-1144
Bourgeron, Thomas
Loth, Eva https://orcid.org/0000-0001-9458-9167
Dell’Acqua, Flavio
Murphy, Declan G. M. https://orcid.org/0000-0002-6664-7451
Puts, Nicolaas A. https://orcid.org/0000-0003-1024-1927
Tillmann, Julian
Charman, Tony https://orcid.org/0000-0003-1993-6549
Jones, Emily J. H.
Mason, Luke
Ambrosino, Sara
Holt, Rosemary
Bölte, Sven https://orcid.org/0000-0002-4579-4970
Buitelaar, Jan K. https://orcid.org/0000-0001-8288-7757
Naaijen, Jilly
- License Information
-
More Information
Article History
Received: 1 June 2022
Revised: 22 December 2022
Accepted: 10 January 2023
First Online: 21 January 2023
Competing interests
: TB served in an advisory or consultancy role for ADHS digital, Infectopharm, Lundbeck, Medice, Neurim Pharmaceuticals, Oberberg GmbH, Roche, and Takeda. He received conference support or speaker’s fee by Medice and Takeda. He received royalities from Hogrefe, Kohlhammer, CIP Medien, Oxford University Press; the present work is unrelated to these relationships. JKB has been in the past 3 years a consultant to/member of advisory board of/and/or speaker for Takeda/Shire, Roche, Medice, Angelini, Janssen, and Servier. He is not an employee of any of these companies, and not a stock shareholder of any of these companies. He has no other financial or material support, including expert testimony, patents, royalties. The remaining authors declare no competing interests.
